Rep. Kevin Hern Sells Shares of Boston Scientific Corporation (NYSE:BSX)

Key Points

• Rep. Kevin Hern sold $1,001–$15,000 of Boston Scientific stock on September 3 from the Gabrielle Ashtyn Hern Trust account, along with multiple sales of other holdings in mid-September.
• Boston Scientific reported quarterly EPS of $0.86 and revenue of $5.44 billion, exceeding analyst expectations, while revenue rose 7.5% year over year. The stock recently traded at $44.10, well below its 12-month high of $105.65.
• Despite several analysts cutting price targets, BSX retains a “Moderate Buy” consensus with an average target of $70.19. Company insiders bought roughly $9.4 million of shares over the past 90 days, including a $9.0 million purchase by CEO Michael Mahoney.

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Boston Scientific Corporation NYSE: BSX. In a filing disclosed on September 25th, the Representative disclosed that they had sold between $1,001 and $15,000 in Boston Scientific stock on September 3rd. The trade occurred in the Representative's "GABRIELLE ASHTYN HERN TRUST" account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of CenterPoint Energy NYSE: CNP on 9/15/2026.
• Sold $1,001 - $15,000 in shares of TJX Companies NYSE: TJX on 9/15/2026.
• Sold $15,001 - $50,000 in shares of STERIS NYSE: STE on 9/15/2026.
• Sold $1,001 - $15,000 in shares of Seagate Technology NASDAQ: STX on 9/15/2026.
• Sold $15,001 - $50,000 in shares of NextEra Energy NYSE: NEE on 9/14/2026.
• Sold $1,001 - $15,000 in shares of Marsh & McLennan Companies NYSE: MRSH on 9/14/2026.
• Sold $15,001 - $50,000 in shares of IQVIA NYSE: IQV on 9/14/2026.
• Sold $15,001 - $50,000 in shares of Home Depot NYSE: HD on 9/14/2026.
• Sold $1,001 - $15,000 in shares of Home Depot NYSE: HD on 9/14/2026.
• Sold $15,001 - $50,000 in shares of Emerson Electric NYSE: EMR on 9/14/2026.

Boston Scientific Trading Up 0.4%

NYSE BSX opened at $44.10 on Tuesday. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The stock's 50-day simple moving average is $46.97 and its two-hundred day simple moving average is $52.24. Boston Scientific Corporation has a twelve month low of $42.20 and a twelve month high of $105.65. The company has a market capitalization of $63.92 billion, a price-to-earnings ratio of 17.86, a PEG ratio of 1.05 and a beta of 0.57.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.83 by $0.03. The company had revenue of $5.44 billion during the quarter, compared to analysts' expectations of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm's revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Research analysts forecast that Boston Scientific Corporation will post 3.27 EPS for the current fiscal year.

Institutional Investors Weigh In On Boston Scientific

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. South Plains Financial Inc. bought a new position in shares of Boston Scientific in the 4th quarter worth about $39,000. Clal Insurance Enterprises Holdings Ltd bought a new stake in Boston Scientific during the first quarter worth about $28,000. Cassaday & Co Wealth Management LLC purchased a new stake in Boston Scientific in the first quarter worth about $32,000. Measured Wealth Private Client Group LLC increased its stake in shares of Boston Scientific by 244.9% during the first quarter. Measured Wealth Private Client Group LLC now owns 545 shares of the medical equipment provider's stock valued at $34,000 after purchasing an additional 387 shares in the last quarter. Finally, Murphy & Mullick Capital Management Corp increased its stake in shares of Boston Scientific by 121.6% during the fourth quarter. Murphy & Mullick Capital Management Corp now owns 565 shares of the medical equipment provider's stock valued at $54,000 after purchasing an additional 310 shares in the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Boston Scientific

In related news, CEO Michael Mahoney purchased 186,240 shares of the company's stock in a transaction dated Monday, August 3rd. The shares were purchased at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the transaction, the chief executive officer directly owned 1,590,024 shares in the company, valued at $76,845,859.92. This trade represents a 13.27% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Edward Ludwig acquired 5,000 shares of the stock in a transaction on Friday, July 31st. The shares were bought at an average price of $45.48 per share, with a total value of $227,400.00. Following the purchase, the director directly owned 30,359 shares of the company's stock, valued at $1,380,727.32. The trade was a 19.72% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 194,522 shares of company stock valued at $9,385,210 in the last ninety days. 0.34% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

BSX has been the topic of several analyst reports. UBS Group decreased their price objective on Boston Scientific from $74.00 to $67.00 and set a "buy" rating on the stock in a report on Thursday, July 30th. Jefferies Financial Group dropped their target price on Boston Scientific from $100.00 to $67.00 and set a "buy" rating for the company in a report on Wednesday, June 24th. Weiss Ratings lowered Boston Scientific from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Tuesday, July 7th. Canaccord Genuity Group lowered their price objective on Boston Scientific from $70.00 to $66.00 and set a "buy" rating for the company in a research report on Thursday, July 30th. Finally, Evercore set a $65.00 price objective on Boston Scientific in a research note on Monday, July 6th. Twenty-three research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $70.19.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma's 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027. Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma's 1st Congressional District. He declared candidacy for the 2026 election. Kevin Hern went into business as a McDonald's franchisee in 1999. He acquired 10 McDonald's franchises by 2012. He served on the McDonald's National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

Boston Scientific Company Profile

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company's portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.